Larvol Delta - EfficacyampSafety-of-ALTB168-in-Patients-With-Moderate-to-Severe-ActiveAntiTNF-Alpha-andor-Antiintegrin-Refractory-UC

neihulizumab (ALTB-168) - AltruBio

http://clinicaltrials.gov/ct2/show/NCT03298022

Jul 6, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next